Could an immunotherapy drug keep kidney cancer from returning after surgery?
NCT ID NCT06584435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can prevent high-risk kidney cancer from coming back after surgery to remove the kidney. About 100 participants will receive the drug every three weeks for up to a year. Researchers will track how long they stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab (an anti-PD-1 antibody)
- What this could lead to
- If it works, this could offer a new option to delay or prevent kidney cancer from coming back after surgery.
- What could go wrong
- This is a small, early-phase study with no comparison group, so results may not be definitive. Side effects from immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changyi Quan
Tianjin, Tianjin Municipality, 300211, China